Increasing prevalence of Gastrointestinal disorders drives the Linaclotide Market

Linaclotide Market Overview 

Product Overview and Scope of Linaclotide 

Linaclotide is a medication used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause. It accelerates the passage of food through the gut by increasing the amount of fluid in the intestines. Linaclotide may improve the consistency of the stool and lessen symptoms such as abdominal pain/discomfort, straining, bloating, and feelings of incomplete bowel movements. Linaclotide works by selectively activating the guanylate cyclase-C (GC-C) receptor in the intestine. This activation increases the concentration of cyclic guanosine monophosphate (cGMP), which in turn leads to increases in the release of chloride and bicarbonate secretion into the intestinal lumen and decreased activity of pain-sensing neurons.  These results help in enhancing bowel motions and reducing pain brought on by specific gastrointestinal disorders.
Linaclotide is primarily indicated for the treatment of two conditions:

1. irritable bowel syndrome with constipation (IBS-C): IBS-C is a common digestive illness characterized by changes in bowel movements, primarily constipation, as well as bloating and stomach pain or discomfort. Constipation and stomach pain are two symptoms of IBS-C that can be treated with linaclotide.
2. Chronic Idiopathic Constipation (CIC): CIC is the term used to describe constipation that does not cause by a structural or metabolic disorder. In CIC patients, linaclotide facilitates better bowel motions and reduces constipation.

Linaclotide Market – Global Industry Analysis

Market Drivers

• Increasing prevalence of gastrointestinal disorders 

The increasing prevalence of gastrointestinal disorders is a major driving factor contributing to the growth of the linaclotide market. Modern lifestyles involve sedentary behavior, unhealthy diets, and high levels of stress. These factors can disrupt digestive processes and contribute to the development of gastrointestinal disorders. Linaclotide has been available for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). 
Gastrointestinal disorders are more common among older individuals. As the global aging population continues to rise, the prevalence of conditions such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and inflammatory bowel disease (IBD) is expected to increase in the coming years. 

Prevalence of gastrointestinal conditions by diagnosis in the U.S. by Gender (2019)

Source: Cognitive Market Research

In recent years, there has been a growing awareness and recognition of gastrointestinal disorders among both healthcare professionals and the general population. This has led to improved diagnostic techniques, earlier detection, and better reporting of these conditions, resulting in an apparent increase in prevalence. This has resulted in an increase in demand for linaclotide medications to treat such types of disorders. In addition, the consumption of processed foods, low-fiber diets, and high levels of refined sugars can lead to digestive problems. These dietary habits are increasingly prevalent, particularly in urban areas and developed countries, contributing to the increased prevalence of gastrointestinal disorders. All these factors contribute to the growth of the linaclotide market.  

• Growing awareness about digestive health among people 
• Rise in the aging population worldwide

Global Linaclotide Revenue by Regions (2018-2023)

Global Linaclotide Revenue and Market Share (%) by regions (2018-2023)

Global Linaclotide Revenue (USD Billion) by regions (2018-2023)

Global Linaclotide market was valued at USD 1.29 billion, in 2022 and is expected to grow at a CAGR of 7.15% over the forecast period, from 2023 to 2030.

Linaclotide Market Segmentation

By Treatment

• Irritable bowel syndrome with constipation (IBS-C)
• Chronic idiopathic constipation (CIC)

By Dosage

• 72 mcg
• 145 mcg
• 290 mcg

By Application

• Tablets
• Capsules

Linaclotide Market, by regions

Linaclotide Market by regions

Source: Cognitive Market Research

In 2022, North America has gained the largest market share. This is due to a well-established healthcare infrastructure, an increasing prevalence of gastrointestinal disorders, and growing awareness about digestive health among people. North America has a well-trained and skilled workforce of healthcare professionals, including doctors, nurses, researchers, and specialists.

Related report:

• Irritable Bowel Syndrome Treatment Market
• Chronic Idiopathic Constipation Drugs Market
• Constipation Treatment Market
• Inflammatory Bowel Disease Treatment Market
• Short Bowel Syndrome Market
• Bowel Irrigation Systems Market

Global Linaclotide Manufacturers Profiles/Analysis

Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. Company Basic Information, and Sales Area

Business Segment/ Overview:

Ironwood Pharmaceuticals, Inc. is a gastrointestinal, or GI, healthcare company specializing in advancing the treatment of GI diseases and redefining the standard of care for GI patients. The company offers innovative products for several areas including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases.

Recent Developments:

Business Strategy

Ironwood Pharmaceuticals, Inc. engaged in strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world.